Eli Lilly and Company (LLY) Given a $73.00 Price Target at BMO Capital Markets
Eli Lilly and Company (NYSE:LLY) has been assigned a $73.00 target price by investment analysts at BMO Capital Markets in a report issued on Monday. The firm currently has a “sell” rating on the stock. BMO Capital Markets’ price objective points to a potential downside of 15.07% from the stock’s current price.
LLY has been the subject of several other research reports. Piper Jaffray Companies reissued a “buy” rating and set a $103.00 price objective on shares of Eli Lilly and in a research report on Thursday, August 31st. Credit Suisse Group downgraded shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and increased their price objective for the stock from $84.23 to $88.00 in a research report on Tuesday, October 10th. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective for the company in a research report on Monday, July 17th. Jefferies Group LLC reissued a “buy” rating and set a $89.00 price objective (down previously from $94.00) on shares of Eli Lilly and in a research report on Thursday, August 24th. Finally, Cowen and Company reaffirmed a “buy” rating and issued a $95.00 target price on shares of Eli Lilly and in a research report on Wednesday, October 4th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the company’s stock. Eli Lilly and currently has an average rating of “Hold” and an average target price of $88.97.
Shares of Eli Lilly and (NYSE LLY) traded down 0.69% during midday trading on Monday, hitting $85.95. 3,800,680 shares of the company’s stock were exchanged. The company has a 50-day moving average of $83.56 and a 200-day moving average of $82.19. Eli Lilly and has a 52 week low of $64.18 and a 52 week high of $89.09. The firm has a market cap of $94.63 billion, a price-to-earnings ratio of 37.05 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The company had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. During the same quarter in the prior year, the firm earned $0.86 earnings per share. The firm’s revenue was up 7.8% compared to the same quarter last year. Equities research analysts expect that Eli Lilly and will post $4.16 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Eli Lilly and Company (LLY) Given a $73.00 Price Target at BMO Capital Markets” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/10/16/eli-lilly-and-company-lly-given-a-73-00-price-target-at-bmo-capital-markets.html.
In other news, major shareholder Lilly Endowment Inc sold 205,000 shares of the firm’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $86.81, for a total transaction of $17,796,050.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders have sold 990,000 shares of company stock valued at $82,949,650. 0.20% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of LLY. Acrospire Investment Management LLC lifted its stake in shares of Eli Lilly and by 16.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after buying an additional 200 shares during the last quarter. MPS Loria Financial Planners LLC acquired a new stake in shares of Eli Lilly and during the 2nd quarter worth about $128,000. San Francisco Sentry Investment Group CA acquired a new stake in shares of Eli Lilly and during the 2nd quarter worth about $129,000. Heritage Trust Co acquired a new stake in shares of Eli Lilly and during the 1st quarter worth about $135,000. Finally, Point72 Asia Hong Kong Ltd lifted its stake in shares of Eli Lilly and by 237.4% during the 1st quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after buying an additional 1,239 shares during the last quarter. Institutional investors own 75.53% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.